LIMN Stock Rises in Pre-Market on Liminatus InnocsAI Deal News
Liminatus Pharma shares moved higher in premarket trading Thursday after the cancer drug company said it plans to buy InnocsAI LLC, a private oncology platform. The deal would sharply increase Liminatus’ share count. LIMN traded at $0.2844 in premarket as of 8:04 a.m. EDT, a jump of 51.4% from the Wednesday close at $0.1878, StockAnalysis said. Premarket trading happens before the main Nasdaq hours.